1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ursodeoxycholic Acid API Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Ursodeoxycholic Acid API by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Ursodeoxycholic Acid API by Country/Region, 2018, 2022 & 2029
2.2 Ursodeoxycholic Acid API Segment by Type
2.2.1 Synthetic UDCA
2.2.2 Extraction UDCA
2.3 Ursodeoxycholic Acid API Sales by Type
2.3.1 Global Ursodeoxycholic Acid API Sales Market Share by Type (2018-2023)
2.3.2 Global Ursodeoxycholic Acid API Revenue and Market Share by Type (2018-2023)
2.3.3 Global Ursodeoxycholic Acid API Sale Price by Type (2018-2023)
2.4 Ursodeoxycholic Acid API Segment by Application
2.4.1 Pharmacy
2.4.2 Health Products
2.5 Ursodeoxycholic Acid API Sales by Application
2.5.1 Global Ursodeoxycholic Acid API Sale Market Share by Application (2018-2023)
2.5.2 Global Ursodeoxycholic Acid API Revenue and Market Share by Application (2018-2023)
2.5.3 Global Ursodeoxycholic Acid API Sale Price by Application (2018-2023)
3 Global Ursodeoxycholic Acid API by Company
3.1 Global Ursodeoxycholic Acid API Breakdown Data by Company
3.1.1 Global Ursodeoxycholic Acid API Annual Sales by Company (2018-2023)
3.1.2 Global Ursodeoxycholic Acid API Sales Market Share by Company (2018-2023)
3.2 Global Ursodeoxycholic Acid API Annual Revenue by Company (2018-2023)
3.2.1 Global Ursodeoxycholic Acid API Revenue by Company (2018-2023)
3.2.2 Global Ursodeoxycholic Acid API Revenue Market Share by Company (2018-2023)
3.3 Global Ursodeoxycholic Acid API Sale Price by Company
3.4 Key Manufacturers Ursodeoxycholic Acid API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ursodeoxycholic Acid API Product Location Distribution
3.4.2 Players Ursodeoxycholic Acid API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Ursodeoxycholic Acid API by Geographic Region
4.1 World Historic Ursodeoxycholic Acid API Market Size by Geographic Region (2018-2023)
4.1.1 Global Ursodeoxycholic Acid API Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Ursodeoxycholic Acid API Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Ursodeoxycholic Acid API Market Size by Country/Region (2018-2023)
4.2.1 Global Ursodeoxycholic Acid API Annual Sales by Country/Region (2018-2023)
4.2.2 Global Ursodeoxycholic Acid API Annual Revenue by Country/Region (2018-2023)
4.3 Americas Ursodeoxycholic Acid API Sales Growth
4.4 APAC Ursodeoxycholic Acid API Sales Growth
4.5 Europe Ursodeoxycholic Acid API Sales Growth
4.6 Middle East & Africa Ursodeoxycholic Acid API Sales Growth
5 Americas
5.1 Americas Ursodeoxycholic Acid API Sales by Country
5.1.1 Americas Ursodeoxycholic Acid API Sales by Country (2018-2023)
5.1.2 Americas Ursodeoxycholic Acid API Revenue by Country (2018-2023)
5.2 Americas Ursodeoxycholic Acid API Sales by Type
5.3 Americas Ursodeoxycholic Acid API Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ursodeoxycholic Acid API Sales by Region
6.1.1 APAC Ursodeoxycholic Acid API Sales by Region (2018-2023)
6.1.2 APAC Ursodeoxycholic Acid API Revenue by Region (2018-2023)
6.2 APAC Ursodeoxycholic Acid API Sales by Type
6.3 APAC Ursodeoxycholic Acid API Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Ursodeoxycholic Acid API by Country
7.1.1 Europe Ursodeoxycholic Acid API Sales by Country (2018-2023)
7.1.2 Europe Ursodeoxycholic Acid API Revenue by Country (2018-2023)
7.2 Europe Ursodeoxycholic Acid API Sales by Type
7.3 Europe Ursodeoxycholic Acid API Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ursodeoxycholic Acid API by Country
8.1.1 Middle East & Africa Ursodeoxycholic Acid API Sales by Country (2018-2023)
8.1.2 Middle East & Africa Ursodeoxycholic Acid API Revenue by Country (2018-2023)
8.2 Middle East & Africa Ursodeoxycholic Acid API Sales by Type
8.3 Middle East & Africa Ursodeoxycholic Acid API Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ursodeoxycholic Acid API
10.3 Manufacturing Process Analysis of Ursodeoxycholic Acid API
10.4 Industry Chain Structure of Ursodeoxycholic Acid API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ursodeoxycholic Acid API Distributors
11.3 Ursodeoxycholic Acid API Customer
12 World Forecast Review for Ursodeoxycholic Acid API by Geographic Region
12.1 Global Ursodeoxycholic Acid API Market Size Forecast by Region
12.1.1 Global Ursodeoxycholic Acid API Forecast by Region (2024-2029)
12.1.2 Global Ursodeoxycholic Acid API Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ursodeoxycholic Acid API Forecast by Type
12.7 Global Ursodeoxycholic Acid API Forecast by Application
13 Key Players Analysis
13.1 ICE
13.1.1 ICE Company Information
13.1.2 ICE Ursodeoxycholic Acid API Product Portfolios and Specifications
13.1.3 ICE Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 ICE Main Business Overview
13.1.5 ICE Latest Developments
13.2 Grindeks
13.2.1 Grindeks Company Information
13.2.2 Grindeks Ursodeoxycholic Acid API Product Portfolios and Specifications
13.2.3 Grindeks Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Grindeks Main Business Overview
13.2.5 Grindeks Latest Developments
13.3 Mitsubishi
13.3.1 Mitsubishi Company Information
13.3.2 Mitsubishi Ursodeoxycholic Acid API Product Portfolios and Specifications
13.3.3 Mitsubishi Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mitsubishi Main Business Overview
13.3.5 Mitsubishi Latest Developments
13.4 Daewoong chemical
13.4.1 Daewoong chemical Company Information
13.4.2 Daewoong chemical Ursodeoxycholic Acid API Product Portfolios and Specifications
13.4.3 Daewoong chemical Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Daewoong chemical Main Business Overview
13.4.5 Daewoong chemical Latest Developments
13.5 PharmaZell GmbH
13.5.1 PharmaZell GmbH Company Information
13.5.2 PharmaZell GmbH Ursodeoxycholic Acid API Product Portfolios and Specifications
13.5.3 PharmaZell GmbH Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 PharmaZell GmbH Main Business Overview
13.5.5 PharmaZell GmbH Latest Developments
13.6 Dipharma Francis
13.6.1 Dipharma Francis Company Information
13.6.2 Dipharma Francis Ursodeoxycholic Acid API Product Portfolios and Specifications
13.6.3 Dipharma Francis Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Dipharma Francis Main Business Overview
13.6.5 Dipharma Francis Latest Developments
13.7 Zhangshanbelling
13.7.1 Zhangshanbelling Company Information
13.7.2 Zhangshanbelling Ursodeoxycholic Acid API Product Portfolios and Specifications
13.7.3 Zhangshanbelling Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Zhangshanbelling Main Business Overview
13.7.5 Zhangshanbelling Latest Developments
13.8 Erregierre
13.8.1 Erregierre Company Information
13.8.2 Erregierre Ursodeoxycholic Acid API Product Portfolios and Specifications
13.8.3 Erregierre Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Erregierre Main Business Overview
13.8.5 Erregierre Latest Developments
13.9 Abil Chempharma
13.9.1 Abil Chempharma Company Information
13.9.2 Abil Chempharma Ursodeoxycholic Acid API Product Portfolios and Specifications
13.9.3 Abil Chempharma Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Abil Chempharma Main Business Overview
13.9.5 Abil Chempharma Latest Developments
13.10 Biotavia Labs
13.10.1 Biotavia Labs Company Information
13.10.2 Biotavia Labs Ursodeoxycholic Acid API Product Portfolios and Specifications
13.10.3 Biotavia Labs Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Biotavia Labs Main Business Overview
13.10.5 Biotavia Labs Latest Developments
13.11 Suzhou Tianlu
13.11.1 Suzhou Tianlu Company Information
13.11.2 Suzhou Tianlu Ursodeoxycholic Acid API Product Portfolios and Specifications
13.11.3 Suzhou Tianlu Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Suzhou Tianlu Main Business Overview
13.11.5 Suzhou Tianlu Latest Developments
13.12 Arcelor Chemicals
13.12.1 Arcelor Chemicals Company Information
13.12.2 Arcelor Chemicals Ursodeoxycholic Acid API Product Portfolios and Specifications
13.12.3 Arcelor Chemicals Ursodeoxycholic Acid API Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Arcelor Chemicals Main Business Overview
13.12.5 Arcelor Chemicals Latest Developments
14 Research Findings and Conclusion
※参考情報 ウルソデオキシコール酸(Ursodeoxycholic Acid、UDCA)は、胆汁酸の一種であり、主に肝臓や胆道において重要な役割を果たしています。この物質は、自然界にも存在する化合物で、特に哺乳類の胆汁中で見られます。UDCAは、主にヒトの腸内で生成される胆汁酸の一部であり、肝臓において代謝される過程で重要な機能を果たしています。そのため、特に肝臓に関連する病気の治療において注目されています。 ウルソデオキシコール酸の特徴としては、以下の点が挙げられます。まず、UDCAは、他の胆汁酸と比べて水溶性が高く、胆汁や腸内での溶解性が優れています。これは、腸内での脂質の消化吸収を助け、肝臓における脂肪肝の改善に寄与します。また、UDCAは、細胞膜に対して保護的な作用を持つため、肝細胞のダメージを軽減し、肝機能の改善に役立つとされています。 ウルソデオキシコール酸には、いくつかの種類が存在しますが、主に医療用途で使用されるのは、合成または抽出された純粋なUDCAです。医薬品としては、通常500mgのカプセルや錠剤として販売され、成人に対しては1日あたり500mgから1500mgの用量が一般的に処方されます。その用途としては、主に肝臓疾患、特に原発性胆汁性胆管炎や非アルコール性脂肪性肝疾患などが挙げられます。 原発性胆汁性胆管炎は、慢性的な肝疾患であり、胆管が破壊され、胆汁の流れが妨げられることにより、肝臓にダメージを与えます。UDCAは、この疾患において胆汁の流れを改善し、肝機能を保護する働きがあります。また、非アルコール性脂肪性肝疾患では、脂肪が肝臓に過剰に蓄積し、炎症や肝障害を引き起こす可能性がありますが、UDCAは脂肪の代謝を促進し、肝組織の炎症を軽減すると考えられています。 さらに、ウルソデオキシコール酸は、胆石の予防や治療にも使用されることがあります。特にコレステロールからなる胆石の溶解に効果があるとされており、一定の条件下で胆石が小さい場合には、UDCAを用いて胆石の溶解を試みることがあります。これによって、外科手術を回避できる可能性があるため、医療現場での需要が高まっています。 関連技術としては、ウルソデオキシコール酸の製造プロセスや評価方法が挙げられます。UDCAは、ライチンなどの動物の胆汁から抽出されることもありますが、現在では化学合成による生産が主流です。この過程は、高純度のUDCAを得るためにさまざまな精製ステップを経ます。また、UDCAの効果を評価するためには、臨床試験が不可欠であり、新たな治療法や用法が開発される際には、多数の患者に対する研究が行われます。 近年では、ウルソデオキシコール酸の新しい応用として、腸内フローラの調整や、腸と肝臓の相互作用に関する研究も進められています。腸内環境が肝機能に及ぼす影響についての理解が深まることで、UDCAが持つ効果が新たに発見される可能性があります。これにより、より効果的な肝疾患の治療法が開発されることが期待されています。 ウルソデオキシコール酸は、肝臓の健康を維持するための重要な側面を持つ医薬品であり、多くの患者にとって有効な治療選択肢であります。今後もさらなる研究と技術の進展が期待され、より広範な疾病に対する治療領域の拡大が進むことでしょう。私たちの健康を保つために、UDCAの持つ可能性についての理解が深まることが重要です。 |